出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2022年4月
HMO市場 : タイプ（2’Fl、3′ Fl、3’Sl、6′ Sl）、用途（乳児用調製粉乳、機能性食品、飲料、栄養補助食品）、濃度（酸性、中性）、地域（北米、ヨーロッパ、APAC、南米、RoW）- 2027年までの世界予測
HMO Market by Type (2’ Fl, 3’ Fl, 3’ Sl, 6’ Sl), Application (Infant Formula, Functional Food & Beverages, Food Supplement), Concentration (Acidic, Neutral) & Region (North America, Europe, APAC, South America, RoW) – Global Forecast to 2027
| ページ数 | 228 |
| 図表数 | 274 |
| 種別 | 英文調査報告書 |
| 価格 |
The global market for HMO market is estimated to be valued at USD 199 million in 2022. It is projected to reach USD 556 million by 2027, recording a CAGR of 22.7% during the forecast period. Human milk oligosaccharides (HMOs) are part of the functional ingredients of breast milk. They are the third most abundant component of milk after lactose and lipids. HMOs act as prebiotics; they support beneficial bacteria growth and have anti-pathogenic effects. Recent studies show that HMOs can boost infant health and reduce disease risk. HMOs are the main nutrients that benefit infants’ growth and are abundantly present in human milk. Currently, HMOs have been synthesized artificially in infant milk formulations to benefit infants who cannot be fed with breast milk, support their growth, and provide them with protection against diseases.
“Asia Pacific is projected to witness the growth of 23.2% during the forecast period.”
The Asia Pacific region accounts USD 92.6 Million of the market size in global market for HMO. The region is expected to grow at the highest CAGR during the forecast period, retaining its dominance as the leading market for HMOs. Asia Pacific is the most densely populated region consisting of countries like China, India, Japan, Australia & New Zealand and Others. It is also one of the key markets for HMOs. China is a dominant market in the region, as it is one of the largest consumers of infant formulas in the world. Hence, any market fluctuation in China is expected to significantly affect the global infant formulas market, which will, in turn, affect the HMO market. China is expected to be the largest market for human milk oligosaccharides (HMO) in 2022. The country has witnessed high adoption of infant formula crafted with premium ingredients, including HMOs, mainly due to the increasing income level, modernization, and middle-class population. The government in China has started easing its stand on the one-child policy and is allowing couples to have two children. This is expected to increase the number of newborn infants, which will, in turn, boost the demand for HMOs.
“The type 2’ FL is gaining rapid popularity in the HMO market across the globe.”
HMOs are known to have Bifidus, a beneficial bacteria species also known as Bifidobacterium. 2’FL selectively grows in intestinal Bifidobacterium because of three different bifidobacterial categories, such as B. dentium, Bifidobacterium bifidum, and B. infantis. On account of their numerous health benefits and a wide array of applications, 2’FL-based HMOs have become popular over the past few years. Various government agencies are granting their approval for their industrial and commercial use. For instances; in July 2021, according to Taiwan Food and Drug Administration, Taiwan authorized the usage of 2’FL Human Milk Oligosaccharides (HMO) in infant formula, milk formula for children aged below seven years, food formula for kids aged below seven years, and growing-up formula. The allowed use of this formula is 1.2g/liter. The 2’FL segment is estimated to dominate the market in 2022, as a result of rigorous and ongoing research in the development of 2’FL-based HMOs by key players.
“Extensive R&D activities by infant formula manufacturers.”
In Infant formula is made from industrially modified. It is intended to be used as a substitute for breast milk and is formulated by manufacturers to mimic the nutritional composition of breast milk for the overall growth and development of infants. According to an article published by the National Library of Medicine in June 2019, from the age of 6 months, an infant’s energy and nutrient requirements start to exceed those provided by breast milk. A lot of research and activities are being conducted by the key market players for developing HMO-based infant formula, baby food etc. for supporting the infant health across the world. Manufacturers involved in the development of infant formulas are constantly engaged in the research and development activities for creating new formulas and ingredients as per the customer requirements. For instance; in January 2019, Nestlé (Switzerland) opened a new R&D center in Ireland. The company made an investment of USD 30.0 million for the same. The center is likely to focus on developing products for infant nutrition. Infant formulas, by providing for the deficiencies, play an important role in the development of infants.
Break-up of Primaries:
By HMO Manufacturers: Managers – 50.0%, Directors – 30.0%, Junior Level Employees – 20.0%
By Designation: Managers – 30.0%, CXOs – 26.0%, and Executives- 44.0%
By Country: India – 55%, US – 20%, UK – 20%, China – 5%
Leading players profiled in this report:
• DSM (Netherlands)
• BASF SE (Germany)
• CHR Hansen Holding A/S (Denmark)
• DUPONT (US)
• Nestle (Switzerland)
• Biosynth Carbosynth (US)
• Inbiose N.V (Belgium)
• Gnubiotics Sciences S.A ( Switzerland)
• Abbott Laboratories (US)
• Royal Friesland Campina N.V (Netherlands)
• Elicityl S.A (France)
• Dextra Laboratories (UK)
Research Coverage:
The report segments the HMO market on the basis of type, end-user, nature, and region. In terms of insights, this report has focused on various levels of analyses—the competitive landscape, end-use analysis, and company profiles, which together comprise and discuss views on the emerging & high-growth segments of the HMO, high-growth regions, countries, government initiatives, drivers, restraints, opportunities, and challenges.
Reasons to buy this report:
• To get a comprehensive overview of the HMO market
• To gain wide-ranging information about the top players in this industry, their product portfolios, and key strategies adopted by them
• To gain insights about the major countries/regions in which the HMO market is flourishing
目次
TABLE OF CONTENTS
1 INTRODUCTION (Page No. – 23)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
FIGURE 1 MARKET SEGMENTATION
TABLE 1 INCLUSIONS AND EXCLUSIONS
1.4 REGIONS COVERED
1.5 PERIODIZATION CONSIDERED
1.6 CURRENCY CONSIDERED
TABLE 2 USD EXCHANGE RATES CONSIDERED, 2017–2021
1.7 UNITS CONSIDERED
1.8 STAKEHOLDERS
1.9 INTRODUCTION TO COVID-19
2 RESEARCH METHODOLOGY (Page No. – 28)
2.1 RESEARCH DATA
FIGURE 2 HUMAN MILK OLIGOSACCHARIDES MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 HUMAN MILK OLIGOSACCHARIDES MARKET SIZE ESTIMATION, BY TYPE (SUPPLY-SIDE)
FIGURE 5 HMO MARKET SIZE ESTIMATION (DEMAND-SIDE)
2.2.1 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 6 HUMAN MILK OLIGOSACCHARIDES MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.2 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 7 HMO MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
2.5 RESEARCH LIMITATIONS & ASSOCIATED RISKS
2.6 MARKET SCENARIOS CONSIDERED FOR THE IMPACT OF COVID-19
2.6.1 SCENARIO-BASED MODELLING
2.7 COVID-19 HEALTH ASSESSMENT
FIGURE 9 COVID-19: GLOBAL PROPAGATION
FIGURE 10 COVID-19 PROPAGATION: SELECT COUNTRIES
2.8 COVID-19 ECONOMIC ASSESSMENT
FIGURE 11 REVISED GROSS DOMESTIC PRODUCT FORECASTS FOR SELECT G20 COUNTRIES IN 2020
2.8.1 COVID-19 ECONOMIC IMPACT—SCENARIO ASSESSMENT
FIGURE 12 CRITERIA IMPACTING GLOBAL ECONOMY
FIGURE 13 SCENARIOS IN TERMS OF RECOVERY OF GLOBAL ECONOMY
3 EXECUTIVE SUMMARY (Page No. – 46)
TABLE 3 HUMAN MILK OLIGOSACCHARIDES MARKET SNAPSHOT, 2022 VS. 2027
FIGURE 14 HUMAN OLIGOSACCHARIDES MARKET, BY TYPE, 2022 VS. 2027
FIGURE 15 HUMAN OLIGOSACCHARIDES MARKET, BY APPLICATION, 2022 VS. 2027
FIGURE 16 HUMAN OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2022 VS. 2027
FIGURE 17 HUMAN MILK OLIGOSACCHARIDES MARKET: REGIONAL SNAPSHOT
4 PREMIUM INSIGHTS (Page No. – 50)
4.1 ATTRACTIVE OPPORTUNITIES IN THE HMO MARKET
FIGURE 18 HUMAN MILK OLIGOSACCHARIDES IMPART MEMORY ENHANCEMENT, GUT HEALTH MAINTENANCE, AND BRAIN DEVELOPMENT TO INFANTS
4.2 HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION
FIGURE 19 ASIA PACIFIC EXPECTED TO DOMINATE THE HUMAN MILK OLIGOSACCHARIDES MARKET BY 2027 IN TERMS OF VALUE
FIGURE 20 ASIA PACIFIC EXPECTED TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD, BY VOLUME TERMS
4.3 HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE
FIGURE 21 2’FL SEGMENT EXPECTED TO ACCOUNT FOR THE LARGEST MARKET SIZE DURING THE FORECAST PERIOD BY VALUE TERMS
FIGURE 22 MARKET FOR 2’FL-BASED HMOS EXPECTED TO ACCOUNT FOR THE LARGEST MARKET SIZE BY 2027 IN TERMS OF VOLUME
4.4 HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION
FIGURE 23 NEUTRAL HUMAN MILK OLIGOSACCHARIDES SEGMENT EXPECTED TO ACCOUNT FOR A LARGER SIZE DURING THE FORECAST PERIOD
4.5 HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION
FIGURE 24 DEMAND FOR HMOS IN INFANT FORMULA APPLICATION EXPECTED TO BE THE HIGHEST DURING THE FORECAST PERIOD
4.6 ASIA PACIFIC: HMO MARKET, BY TYPE & KEY COUNTRY
FIGURE 25 CHINA AND 2’FL MARKET SEGMENTS ACCOUNTED FOR A SIGNIFICANT SHARE IN THE HUMAN MILK OLIGOSACCHARIDES MARKET
FIGURE 26 CANADA, THE US, MEXICO, AND CHINA EXPECTED TO GROW AT A SIGNIFICANT RATE DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. – 56)
5.1 INTRODUCTION
5.2 MACROECONOMIC INDICATORS
5.2.1 DIGITALIZATION OF THE RETAIL INDUSTRY
FIGURE 27 EU: ONLINE PURCHASES OF GOODS & SERVICES, 2018
5.2.2 RISE IN THE NUMBER OF DUAL-INCOME HOUSEHOLDS
FIGURE 28 US: EMPLOYMENT STATUS OF PARENTS WITH CHILDREN UNDER 18 YEARS, 2020
5.2.3 RAPID URBANIZATION ACROSS REGIONS
FIGURE 29 URBAN AND RURAL POPULATIONS IN THE WORLD, 2016–2020
5.3 MARKET DYNAMICS
FIGURE 30 MARKET DYNAMICS
5.3.1 DRIVERS
5.3.1.1 Rise in the infant population
FIGURE 31 GROWTH IN INFANT POPULATION, 2010–2020 (THOUSAND)
5.3.1.2 Growth in health awareness leading to increased consumption of dietary supplements
FIGURE 32 US: DIETARY CONSUMPTION RATE, BY AGE GROUP, 2020
5.3.1.3 Extensive R&D initiatives by companies operating in the infant formula market
5.3.2 RESTRAINTS
5.3.2.1 Higher production costs associated with the development of HMO-composed supplements and food products
5.3.2.2 Stringent regulations and trade policies in the infant formula and dietary supplement industries
5.3.3 OPPORTUNITIES
5.3.3.1 Emergence of alternative animal milk oligosaccharides
5.3.3.2 Adoption of advanced technologies in the functional food industry
5.3.4 CHALLENGES
5.3.4.1 Complex industrial process to extract oligosaccharides from milk
5.3.4.2 Lack of consumer awareness regarding benefits associated with HMO-formulated products
5.4 KEY CONFERENCES & EVENTS
TABLE 4 HUMAN MILK OLIGOSACCHARIDES MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2022–2023
5.5 KEY STAKEHOLDERS & BUYING CRITERIA
5.5.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
TABLE 5 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 MODES OF APPLICATIONS
5.5.2 BUYING CRITERIA
FIGURE 33 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS
TABLE 6 KEY BUYING CRITERIA FOR TOP 3 MODES OF APPLICATION
6 INDUSTRY TRENDS (Page No. – 66)
6.1 OVERVIEW
6.2 REGULATORY FRAMEWORK
6.3 NORTH AMERICA
6.3.1 CANADA
6.3.2 US
6.3.3 MEXICO
6.4 EUROPEAN UNION (EU)
6.5 ASIA PACIFIC
6.5.1 JAPAN
6.5.2 CHINA
6.5.3 INDIA
6.5.4 AUSTRALIA & NEW ZEALAND
6.6 SOUTH AMERICA
6.6.1 BRAZIL
6.6.2 ARGENTINA
6.7 REST OF THE WORLD (ROW)
6.7.1 MIDDLE EAST
6.8 REGULATORY BODIES
6.9 PATENT ANALYSIS
FIGURE 34 HUMAN MILK OLIGOSACCHARIDES MARKET: PATENT ANALYSIS, BY APPLICANT, 2017–2021
FIGURE 35 HMO MARKET: PATENT ANALYSIS, BY REGION, 2017–2021
FIGURE 36 HMO MARKET: PATENT ANALYSIS, BY LEGAL STATUS, 2017–2021
TABLE 7 RECENT PATENTS GRANTED WITH RESPECT TO HMOS
6.10 VALUE CHAIN ANALYSIS
FIGURE 37 VALUE CHAIN ANALYSIS
6.11 COVID-19 IMPACT ON THE HUMAN MILK OLIGOSACCHARIDES MARKET
6.12 TREND/DISRUPTION IMPACTING BUYERS IN THE HUMAN MILK OLIGOSACCHARIDES MARKET
FIGURE 38 REVENUE SHIFT FOR THE HUMAN MILK OLIGOSACCHARIDES MARKET
6.13 MARKET ECOSYSTEM
TABLE 8 HMO MARKET: ECOSYSTEM
6.14 TECHNOLOGY ANALYSIS
6.14.1 HIGH-PERFORMANCE ANION-EXCHANGE CHROMATOGRAPHY FOR HUMAN MILK OLIGOSACCHARIDES ANALYSIS
6.14.2 CAPILLARY ELECTROPHORESIS FOR HUMAN MILK OLIGOSACCHARIDES ANALYSIS
6.15 PORTER’S FIVE FORCES ANALYSIS
TABLE 9 PORTER’S FIVE FORCES ANALYSIS
6.15.1 INTENSITY OF COMPETITIVE RIVALRY
6.15.2 BARGAINING POWER OF SUPPLIERS
6.15.3 BARGAINING POWER OF BUYERS
6.15.4 THREAT OF SUBSTITUTES
6.15.5 THREAT OF NEW ENTRANTS
6.16 CASE STUDY ANALYSIS
6.16.1 USE CASE 1: LAYER ORIGIN INTRODUCED EASY-TO-USE AND EFFICIENT-TO-HMO PREBIOTIC PILLS AND POWDER FOR ADULTS
6.17 PRICE ANALYSIS
6.17.1 INTRODUCTION
6.17.2 PRICE ANALYSIS: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017-2021 (USD PER/KG)
6.17.3 PRICE ANALYSIS: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017-2021 (USD PER/KG)
7 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY TYPE (Page No. – 80)
7.1 INTRODUCTION
FIGURE 39 HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
TABLE 10 HMO MARKET, BY TYPE, 2017–2021 (TONS)
TABLE 11 HMO MARKET, BY TYPE, 2022–2027 (TONS)
TABLE 12 HMO MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 13 HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
7.1.1 HUMAN MILK OLIGOSACCHARIDES MARKET: COVID-19 IMPACT ANALYSIS – BY TYPE
TABLE 14 REALISITIC SCENARIO: COVID-19 IMPACT ANALYSIS OF THE HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2022 (USD MILLION)
TABLE 15 OPTIMISTIC SCENARIO: COVID-19 IMPACT ANALYSIS OF THE HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2017–2022 (USD MILLION)
TABLE 16 PESSIMISTIC SCENARIO: COVID-19 IMPACT ANALYSIS OF THE HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2017–2022 (USD MILLION)
7.2 2’FL
7.2.1 AUTHORIZATION OF HMOS BY GOVERNMENT BODIES FOR CONSUMPTION
TABLE 17 2’FL: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
TABLE 18 2’FL: HMO MARKET, BY REGION, 2022–2027 (USD MILLION)
TABLE 19 2’FL: HMO MARKET, BY REGION, 2017–2021 (TONS)
TABLE 20 2’FL: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2022–2027 (TONS)
7.3 3’FL
7.3.1 PREBIOTIC QUALITY OF 3’FL EXPECTED TO PROPEL THE GROWTH OF THE HUMAN MILK OLIGOSACCHARIDES MARKET IN THE UPCOMING YEARS
TABLE 21 3’FL: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
TABLE 22 3’FL: HMO MARKET, BY REGION, 2022–2027 (USD MILLION)
TABLE 23 3’FL: HMO MARKET, BY REGION, 2017–2021 (TONS)
TABLE 24 3’FL: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2022–2027 (TONS)
7.4 3’SL
7.4.1 SIGNIFICANCE OF 3’SL IN LANGUAGE DEVELOPMENT DURING EARLY CHILDHOOD
TABLE 25 3’SL: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
TABLE 26 3’SL: HMO MARKET, BY REGION, 2022–2027 (USD MILLION)
TABLE 27 3’SL: HMO MARKET, BY REGION, 2017–2021 (TONS)
TABLE 28 3’SL: HMO MARKET, BY REGION, 2022–2027 (TONS)
7.5 6’SL
7.5.1 WIDE USAGE OF HMOS ACROSS INDUSTRIES
TABLE 29 6’SL: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
TABLE 30 6’SL: HMO MARKET, BY REGION, 2022–2027 (USD MILLION)
TABLE 31 6’SL: HMO MARKET, BY REGION, 2017–2021 (TONS)
TABLE 32 6’SL: HMO MARKET, BY REGION, 2022–2027 (TONS)
8 HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION (Page No. – 93)
8.1 INTRODUCTION
FIGURE 40 HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
TABLE 33 HMO MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
TABLE 34 HMO MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
8.1.1 EXTENSIVE R&D ACTIVITIES BY INFANT FORMULA MANUFACTURERS
TABLE 35 INFANT FORMULA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
TABLE 36 INFANT FORMULA: HMO MARKET, BY REGION, 2022–2027 (USD MILLION)
8.2 FUNCTIONAL FOOD & BEVERAGES
8.2.1 ROLE OF FAST-PACED LIFESTYLE AND GROWING ADOPTION OF CONVENIENCE FOOD PRODUCTS IN THE GROWTH OF FUNCTIONAL FOOD & BEVERAGES
TABLE 37 FUNCTIONAL FOOD & BEVERAGES: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
TABLE 38 FUNCTIONAL FOOD & BEVERAGES: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2022–2027 (USD MILLION)
8.3 FOOD SUPPLEMENTS
8.3.1 GROWING HEALTH AWARENESS AND DEMAND FOR NUTRITION-RICH FOOD PRODUCTS
TABLE 39 FOOD SUPPLEMENTS: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
TABLE 40 FOOD SUPPLEMENTS: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2022–2027 (USD MILLION)
8.4 OTHER APPLICATIONS
8.4.1 WIDE USAGE OF HMOS ACROSS INDUSTRIES
TABLE 41 OTHER APPLICATIONS: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
TABLE 42 OTHER APPLICATIONS: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2022–2027 (USD MILLION)
9 HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION (Page No. – 101)
9.1 INTRODUCTION
FIGURE 41 HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2022 VS. 2027 (USD MILLION)
TABLE 43 HMO MARKET, BY CONCENTRATION, 2017–2021 (USD MILLION)
TABLE 44 HMO MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
9.2 NEUTRAL
9.2.1 RISING CONSUMER CONCERNS REGARDING GUT HEALTH AND IMMUNITY IN INFANTS
TABLE 45 NEUTRAL: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
TABLE 46 NEUTRAL: HMO MARKET, BY REGION, 2022–2027 (USD MILLION)
9.3 ACIDIC
9.3.1 IMITATION OF HUMAN MILK IN PREMIUM INFANT FORMULAS
TABLE 47 ACIDIC: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
TABLE 48 ACIDIC: HMO MARKET, BY REGION, 2022–2027 (USD MILLION)
10 HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET, BY REGION (Page No. – 106)
10.1 INTRODUCTION
FIGURE 42 CHINA EXPECTED TO ACCOUNT FOR THE LARGEST SHARE IN THE HUMAN MILK OLIGOSACCHARIDES MARKET IN 2022
FIGURE 43 HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
TABLE 49 GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2021 (USD MILLION)
FIGURE 50 GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2022–2027 (USD MILLION)
FIGURE 51 GLOBAL HMO MARKET, BY REGION, 2017–2021 (TONS)
FIGURE 52 GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2022–2027 (TONS)
TABLE 53 GLOBAL HMO MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 54 GLOBAL HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
TABLE 55 GLOBAL HMO MARKET, BY TYPE, 2017–2021 (TONS)
TABLE 56 GLOBAL HMO MARKET, BY TYPE, 2022–2027 (TONS)
TABLE 57 GLOBAL HMO MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
TABLE 58 GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
TABLE 59 GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2017–2021(USD MILLION)
TABLE 60 GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
10.2 HUMAN MILK OLIGOSACCHARIDES MARKET: COVID-19 IMPACT ANALYSIS – BY REGION
TABLE 61 REALISITIC SCENARIO: COVID-19 IMPACT ANALYSIS OF THE HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2022 (USD MILLION)
TABLE 62 OPTIMISTIC SCENARIO: COVID-19 IMPACT ANALYSIS OF THE HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2022 (USD MILLION)
TABLE 63 PESSIMISTIC SCENARIO: COVID-19 IMPACT ANALYSIS OF THE HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2017–2022 (USD MILLION)
10.3 NORTH AMERICA
FIGURE 44 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES MARKET SNAPSHOT, 2022
TABLE 64 NORTH AMERICA: HMO MARKET, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 65 NORTH AMERICA: HMO MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
TABLE 66 NORTH AMERICA: HMOMARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 67 NORTH AMERICA: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
TABLE 68 NORTH AMERICA: HMO MARKET, BY TYPE, 2017–2021 (TONS)
TABLE 69 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (TONS)
TABLE 70 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
TABLE 71 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
TABLE 72 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2017–2021 (USD MILLION)
TABLE 73 NORTH AMERICA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
10.3.1 US
10.3.1.1 Increased demand from end-user companies, such as Nestlé S.A. (Switzerland) and Danone S.A. (France)
TABLE 74 US: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 75 US: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.3.2 CANADA
10.3.2.1 Cronobacter Sakazakii or Salmonella Newport infection among infants hindering the Canadian human milk oligosaccharides market
TABLE 76 CANADA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 77 CANADA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.3.3 MEXICO
10.3.3.1 Rise in per capita expenditure on nutritious and healthy foods estimated to boost the market
TABLE 78 MEXICO: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 79 MEXICO: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.4 EUROPE
TABLE 80 EUROPE: HUMAN MILK OLIGOSACCHARIDES MARKET, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 81 EUROPE: HMO MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
TABLE 82 EUROPE: HMO MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 83 EUROPE: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
TABLE 84 EUROPE: HMO MARKET, BY TYPE, 2017–2021 (TONS)
TABLE 85 EUROPE: HMO MARKET, BY TYPE, 2022–2027 (TONS)
TABLE 86 EUROPE: HMO MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
TABLE 87 EUROPE: HMO MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
TABLE 88 EUROPE: HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2017–2021 (USD MILLION)
TABLE 89 EUROPE: HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
10.4.1 GERMANY
10.4.1.1 Continuous research and development in the HMO segment
TABLE 90 GERMANY: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 91 GERMANY: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.4.2 UK
10.4.2.1 Introduction of HMO-based infant formulas
TABLE 92 UK: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 93 UK: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.4.3 FRANCE
10.4.3.1 Strategic initiatives taken by local players
TABLE 94 FRANCE: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 95 FRANCE: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.4.4 SPAIN
10.4.4.1 Consumer preference for clean-label ingredients paving the way for 2’FL dietary supplement products
TABLE 96 SPAIN: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 97 SPAIN: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.4.5 ITALY
10.4.5.1 Increasing popularity of HMO-based adult supplements
TABLE 98 ITALY: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 99 ITALY: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.4.6 REST OF EUROPE
10.4.6.1 Aggressive marketing around infant formulas and misleading health claims hindering human milk oligosaccharides market growth
TABLE 100 REST OF EUROPE: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 101 REST OF EUROPE: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.5 ASIA PACIFIC
FIGURE 45 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES MARKET SNAPSHOT, 2022
TABLE 102 ASIA PACIFIC: HMO MARKET, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 103 ASIA PACIFIC: HMO MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
TABLE 104 ASIA PACIFIC: HMO MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 105 ASIA PACIFIC: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
TABLE 106 ASIA PACIFIC: HMO MARKET, BY TYPE, 2017–2021 (TONS)
TABLE 107 ASIA PACIFIC: HMO MARKET, BY TYPE, 2022–2027 (TONS)
TABLE 108 ASIA PACIFIC: HMO MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
TABLE 109 ASIA PACIFIC: HMO MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
TABLE 110 ASIA PACIFIC: HMO MARKET, BY CONCENTRATION, 2017–2021 (USD MILLION)
TABLE 111 ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
10.5.1 CHINA
10.5.1.1 Continuous research & development in the field of HMO expected to expand the market
TABLE 112 CHINA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 113 CHINA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.5.2 INDIA
10.5.2.1 Millennial population playing an important role in driving the demand for HMO-based food products
TABLE 114 INDIA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 115 INDIA: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.5.3 JAPAN
10.5.3.1 Stringent rules and regulations by the Japanese government bodies challenging human milk oligosaccharides market growth
TABLE 116 JAPAN: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 117 JAPAN: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.5.4 AUSTRALIA & NEW ZEALAND
10.5.4.1 Approval for the use of 2’FL HMOs in infant formula
TABLE 118 AUSTRALIA & NEW ZEALAND: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 119 AUSTRALIA & NEW ZEALAND: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.5.5 REST OF ASIA PACIFIC
10.5.5.1 Strategic decisions undertaken
TABLE 120 REST OF ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 121 REST OF ASIA PACIFIC: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.6 SOUTH AMERICA
TABLE 122 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 123 SOUTH AMERICA: HMO MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
TABLE 124 SOUTH AMERICA: HMO MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 125 SOUTH AMERICA: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
TABLE 126 SOUTH AMERICA: HMO MARKET, BY TYPE, 2017–2021 (TONS)
TABLE 127 SOUTH AMERICA: HMO MARKET, BY TYPE, 2022–2027 (TONS)
TABLE 128 SOUTH AMERICA: HMO MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
TABLE 129 SOUTH AMERICA: HMO MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
TABLE 130 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2017–2021 (USD MILLION)
TABLE 131 SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
10.6.1 BRAZIL
10.6.1.1 Infant formulas gaining popularity due to their ease of use
TABLE 132 BRAZIL: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 133 BRAZIL: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.6.2 ARGENTINA
10.6.2.1 Growing inclination toward functional food
TABLE 134 ARGENTINA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 135 ARGENTINA: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.6.3 REST OF SOUTH AMERICA
10.6.3.1 Influence of health and wellness trends
TABLE 136 REST OF SOUTH AMERICA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 137 REST OF SOUTH AMERICA: HMO MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.7 REST OF THE WORLD (ROW)
TABLE 138 ROW: HUMAN MILK OLIGOSACCHARIDES MARKET, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 139 ROW: HUMAN MILK OLIGOSACCHARIDES MARKET, BY COUNTRY, 2022–2027 (USD MILLION)
TABLE 140 ROW: HMO MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 141 ROW: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (USD MILLION)
TABLE 142 ROW: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (TONS)
TABLE 143 ROW: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (TONS)
TABLE 144 ROW: HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2017–2021 (USD MILLION)
TABLE 145 ROW: HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2022–2027 (USD MILLION)
TABLE 146 ROW: HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2017–2021 (USD MILLION)
TABLE 147 ROW: HUMAN MILK OLIGOSACCHARIDES MARKET, BY CONCENTRATION, 2022–2027 (USD MILLION)
10.7.1 MIDDLE EAST
10.7.1.1 Complementary food feeding among infants
TABLE 148 MIDDLE EAST: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 149 MIDDLE EAST: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (USD MILLION)
10.7.2 AFRICA
10.7.2.1 Prevalence of vitamin deficiency among women and children
TABLE 150 AFRICA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2017–2021 (USD MILLION)
TABLE 151 AFRICA: HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2022–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. – 156)
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS, 2021
TABLE 152 HUMAN MILK OLIGOSACCHARIDES MARKET: DEGREE OF COMPETITION
11.3 KEY PLAYER STRATEGIES
11.4 HISTORICAL REVENUE ANALYSIS OF KEY PLAYERS
FIGURE 46 THREE-YEAR TOTAL REVENUE ANALYSIS OF KEY PLAYERS IN THE MARKET, 2019–2021 (USD BILLION)
11.5 COVID-19-SPECIFIC COMPANY RESPONSE
11.5.1 DSM
11.5.2 BASF SE
11.5.3 DUPONT
11.5.4 CHR HANSEN HOLDING A/S
11.6 COMPANY EVALUATION QUADRANT (KEY PLAYERS)
11.6.1 STARS
11.6.2 EMERGING LEADERS
11.6.3 PERVASIVE PLAYERS
11.6.4 PARTICIPANTS
FIGURE 47 HUMAN MILK OLIGOSACCHARIDES MARKET: COMPANY EVALUATION QUADRANT, 2021 (KEY PLAYERS)
11.7 PRODUCT FOOTPRINT
TABLE 153 COMPANY, BY TYPE FOOTPRINT
TABLE 154 COMPANY, BY APPLICATION FOOTPRINT
TABLE 155 COMPANY, BY REGIONAL FOOTPRINT
TABLE 156 COMPANY, BY OVERALL FOOTPRINT
11.8 START-UP/SME EVALUATION QUADRANT (OTHER PLAYERS)
11.8.1 PROGRESSIVE COMPANIES
11.8.2 STARTING BLOCKS
11.8.3 RESPONSIVE COMPANIES
11.8.4 DYNAMIC COMPANIES
TABLE 157 DETAILED LIST OF KEY STARTUP/SMES
TABLE 158 HUMAN MILK OLIGOSACCHARIDES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SMES
FIGURE 48 HUMAN MILK OLIGOSACCHARIDES MARKET: COMPANY EVALUATION QUADRANT, 2021 (OTHER PLAYERS)
11.9 COMPETITIVE SCENARIO
11.9.1 NEW PRODUCT LAUNCHES
TABLE 159 HUMAN MILK OLIGOSACCHARIDES MARKET: NEW PRODUCT LAUNCHES, 2018–2021
11.9.2 DEALS
TABLE 160 HUMAN MILK OLIGOSACCHARIDES MARKET: DEALS, 2018–2021
12 COMPANY PROFILES (Page No. – 172)
12.1 KEY PLAYERS
(Business overview, Products offered, Recent Developments, MNM view)*
12.1.1 DSM
TABLE 161 DSM: BUSINESS OVERVIEW
FIGURE 49 DSM: COMPANY SNAPSHOT
TABLE 162 DSM: PRODUCTS OFFERED
TABLE 163 DSM: DEALS
12.1.2 BASF SE.
TABLE 164 BASF SE.: BUSINESS OVERVIEW
FIGURE 50 BASF SE.: COMPANY SNAPSHOT
TABLE 165 BASF SE.: PRODUCTS OFFERED
TABLE 166 BASF SE: NEW PRODUCT LAUNCHES
TABLE 167 BASF SE.: DEALS
12.1.3 CHR HANSENHOLDING A/S
TABLE 168 CHR HANSEN HOLDING A/S: BUSINESS OVERVIEW
FIGURE 51 CHR. HANSEN HOLDINGS A/S: COMPANY SNAPSHOT
TABLE 169 CHR. HANSEN HOLDINGS A/S: PRODUCTS OFFERED
TABLE 170 CHR. HANSEN HOLDING A/S: DEALS
12.1.4 DUPONT
TABLE 171 DUPONT: BUSINESS OVERVIEW
FIGURE 52 DUPONT: COMPANY SNAPSHOT
TABLE 172 DUPONT: PRODUCTS OFFERED
TABLE 173 DUPONT: NEW PRODUCT LAUNCHES
TABLE 174 DUPONT: DEALS
12.1.5 NESTLE
TABLE 175 NESTLE: BUSINESS OVERVIEW
FIGURE 53 NESTLE: COMPANY SNAPSHOT
TABLE 176 NESTLE: PRODUCTS OFFERED
TABLE 177 NESTLE: NEW PRODUCT LAUNCHES
12.1.6 BIOSYNTH CARBOSYNTH
TABLE 178 BIOSYNTH CARBOSYNTH: BUSINESS OVERVIEW
TABLE 179 BIOSYNTH CARBOSYNTH: PRODUCTS OFFERED
TABLE 180 BIOSYNTH CARBOSYNTH: DEALS
12.1.7 INBIOSE NV.
TABLE 181 INBIOSE NV.: BUSINESS OVERVIEW
TABLE 182 INBIOSE NV: PRODUCTS OFFERED
12.1.8 GNUBIOTICS SCIENCES S.A.
TABLE 183 GNUBIOTICS SCIENCES S.A.: BUSINESS OVERVIEW
TABLE 184 GNUBIOTICS SCIENCES S.A.: PRODUCTS OFFERED
TABLE 185 GNUBIOTICS SCIENCES S.A.: NEW PRODUCT LAUNCHES
12.1.9 ABBOTT LABORATORIES
TABLE 186 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 54 ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 187 ABBOTT LABORATORIES: PRODUCTS OFFERED
TABLE 188 ABBOTT LABORATORIES: NEW PRODUCT LAUNCHES
12.1.10 ROYAL FRIESLANDCAMPINA N.V
TABLE 189 ROYAL FRIESLANDCAMPINA N.V: BUSINESS OVERVIEW
FIGURE 55 ROYAL FRIESLANDCAMPINA N.V: COMPANY SNAPSHOT
TABLE 190 ROYAL FRIESLANDCAMPINA N.V: PRODUCTS OFFERED
TABLE 191 ROYAL FRIESLANDCAMPINA N.V: NEW PRODUCT LAUNCHES
TABLE 192 ROYAL FRIESLANDCAMPINA N.V: DEALS
12.1.11 ELICITYL S.A
TABLE 193 ELICITYL S.A.: BUSINESS OVERVIEW
TABLE 194 ELICITYL S.A: PRODUCTS OFFERED
12.1.12 DEXTRA LABORATORIES LTD.
TABLE 195 DEXTRA LABORATORIES LTD.: BUSINESS OVERVIEW
TABLE 196 DEXTRA LABORATORIES LTD.: PRODUCTS OFFERED
12.2 START-UPS/SME’S/OTHER PLAYERS
12.2.1 ZUCHEM INC.
TABLE 197 ZUCHEM INC.: COMPANY OVERVIEW
12.2.2 ADVANCED PROTEIN TECHNOLOGIES CORP.
TABLE 198 ADVANCED PROTEIN TECHNOLOGIES CORP.: COMPANY OVERVIEW
12.2.3 CONAGEN INC.
TABLE 199 CONAGEN INC.: COMPANY OVERVIEW
12.2.4 KYOWA HAKKO BIO CO. LTD.
TABLE 200 KYOWA HAKKA BIO CO. LTD.: COMPANY OVERVIEW
12.2.5 MEDOLAC LABORATORIES
TABLE 201 MEDOLAC LABORATORIES: COMPANY OVERVIEW
12.3 END USER COMPANY PROFILES
12.3.1 H & H GROUP
TABLE 202 H&H GROUP: BUSINESS OVERVIEW
TABLE 203 H&H GROUP: PRODUCTS OFFERED
12.3.2 LAYER ORIGIN NUTRITION
TABLE 204 LAYER ORIGIN NUTRITION: BUSINESS OVERVIEW
TABLE 205 LAYER ORIGIN NUTRITION: PRODUCTS OFFERED
12.3.3 STANDARD PROCESS INC.
TABLE 206 STANDARD PROCESS INC.: BUSINESS OVERVIEW
TABLE 207 STANDARD PROCESS INC.: PRODUCTS OFFERED
12.3.4 RECKITT BENCKISER GROUP
TABLE 208 RECKITT BENCKISER GROUP: BUSINESS OVERVIEW
TABLE 209 RECKITT BENCKISER GROUP: PRODUCTS OFFERED
12.3.5 AMAZON
TABLE 210 AMAZON: BUSINESS OVERVIEW
TABLE 211 AMAZON: PRODUCTS OFFERED
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
13 ADJACENT & RELATED MARKETS (Page No. – 210)
13.1 INTRODUCTION
13.2 INFANT FORMULA INGREDIENTS MARKET
13.2.1 LIMITATIONS
13.2.2 MARKET DEFINITION
13.2.3 MARKET OVERVIEW
13.2.4 INFANT FORMULA INGREDIENTS MARKET, BY INGREDIENT
TABLE 212 INFANT FORMULA INGREDIENTS MARKET SIZE, BY INGREDIENT, 2017–2025 (USD MILLION)
TABLE 213 INFANT FORMULA INGREDIENTS MARKET SIZE, BY INGREDIENT, 2017–2025 (KT)
13.2.5 INFANT FORMULA INGREDIENTS MARKET, BY REGION
TABLE 214 INFANT FORMULA INGREDIENTS MARKET SIZE, BY REGION, 2017–2025 (USD BILLION)
TABLE 215 INFANT FORMULA INGREDIENTS MARKET SIZE, BY REGION, 2017–2025 (KT)
13.3 FUNCTIONAL FOOD INGREDIENTS MARKET
13.3.1 LIMITATIONS
13.3.2 MARKET DEFINITION
13.3.3 MARKET OVERVIEW
13.3.4 FUNCTIONAL FOOD INGREDIENTS MARKET, BY TYPE
TABLE 216 FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY TYPE, 2016–2020 (USD MILLION)
TABLE 217 FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY TYPE, 2021–2026 (USD MILLION)
13.3.5 FUNCTIONAL FOOD INGREDIENTS MARKET, BY REGION
TABLE 218 FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY REGION, 2016–2020 (USD MILLION)
TABLE 219 FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY REGION, 2021–2026 (USD MILLION)
14 APPENDIX (Page No. – 220)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS